SLC5A2 and type 2 diabetes mellitus: In addition, the performance of phytocannabinoid-based therapeutics can be compared directly to existing synthetic SGLT2 inhibitor medications, and the comparison may suggest additional targets to explore to alleviate T2DM that synthetic SGLT2 inhibitors are not capable of targeting [79].